A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
A phase 3 trial of Xembify in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Grifols Therapeutics LLC, now recruiting.
Overview
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT05645107 by Grifols Therapeutics LLC, with 386 participants planned, started 2022-12-26 and due to reach its primary completion in 2029-08. Interventions recorded: Xembify and Placebo.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Shares Grifols, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.